title: Neurologic complications of infective endocarditis.
abstract: The average overall incidence of neurologic complications in patients with infective endocarditis is 30%, with the vast majority of these complications in patients with left-sided valvular disease. The incidence of central nervous system manifestations, particularly of embolic events, tends to be higher in cases of endocarditis caused by more virulent organisms, such as S. aureus and the Enterobacteriaceae. The clinical presentation is dependent on the area of the central nervous system involved. CT and MRI scanning are useful radiologic imaging techniques for the diagnosis of central nervous system complications in patients with infective endocarditis; cerebral angiography should be used in patients with suspected intracranial mycotic aneurysm. The cornerstone of management is appropriate antimicrobial therapy. Neurosurgical intervention may be required for certain patients with intracranial mycotic aneurysms that do not disappear after antimicrobial therapy or for aneurysms that enlarge or bleed. Anticoagulants should be continued in patients with prosthetic valve endocarditis who do not have evidence of intracranial hemorrhage. Anticoagulants should be avoided (unless thromboembolic events are from a site other than the vegetation) in patients with native valve endocarditis owing to the risk of hemorrhagic central nervous system complications. Case fatality rates tend to be higher in patients with neurologic complications of infective endocarditis. Earlier diagnostic and therapeutic interventions for patients with central nervous system complications of infective endocarditis will, it is hoped, improve the outcome in patients with this disorder.
authors.affiliation: Division of Infectious Diseases, Medical College of Pennsylvania, Philadelphia.
authors.forename: A R
authors.initials: AR
authors.lastname: Tunkel
authors.forename: D
authors.initials: D
authors.lastname: Kaye
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D001922:Brain Abscess / Q000150:complications / Q000503:physiopathology; D001927:Brain Diseases / Q000209:etiology / Q000503:physiopathology; D004698:Endocarditis, Subacute Bacterial / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D006351:Heart Valves / Q000382:microbiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008581:Meningitis / Q000150:complications / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000302:isolation & purification*; D013296:Streptococcus pneumoniae / Q000302:isolation & purification*; D013923:Thromboembolism / Q000209:etiology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D000925:Anticoagulants